MedBeats
Breaking news and information from the CDC, FDA and nursing journals.
Increasing Threat of Spread of Antimicrobial-resistant Fungus in Healthcare Facilities
C. auris case counts may also have increased because of enhanced efforts to detect cases, including increased colonization screening, a test to see if someone has the fungus somewhere on their body but does not have an infection or symptoms of infection.
Read MoreUpdate - Monkeypox in People with HIV, Children and Adolescents, and People who are Pregnant or Breastfeeding
Update for Clinicians: People with HIV, individuals who are immunocompromised, children, adolescents, and people who are pregnant or breastfeeding may be at risk
Read MoreFDA Withdrawn Approval of Lymphoma Medicine Due to Safety Concerns
Stop prescribing Ukoniq and switch patients to alternative treatments. Inform patients currently taking Ukoniq of the increased risk of death seen in the clinical trial and advise them to stop taking the medicine.
Read MoreTelehealth Privacy and Security Tips
Buzz, a HIPAA-complaint platform enables providers to conduct secure video conferences or calls with patients quickly, easily & seamlessly.
Read MoreFDA Recall - COVID-19 Antigen Tests (Nasal/Saliva) and COVID-19 IgG/IgM Antibody Tests by LuSys Laboratories
The quadrivalent HPV vaccine provides durable protection against anogenital disease related to HPV6, 11, 16, and 18.
Read MoreCoronavirus Infections Update: January 2022
The Omicron has become the predominant virus type in many countries and it has substantially increased the number of COVID-19 cases as compared with the earlier situation.
Read MoreSustainability of Neutralising Antibodies Induced by Bivalent or Quadrivalent HPV Vaccines
Significant differences in the immunogenicity of the two vaccines are in line with the differences in their cross-protective efficacy. Protective HPV vaccine-induced antibody titres can be detected up to 12 years after vaccination.
Read MoreLong-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection
The results support the durability of long-acting cabotegravir and rilpivirine, over an almost 2-year-long period, as a therapeutic option for virally suppressed adults with HIV-1.
Read MoreFDA Authorizes T-Detect COVID Test
FDA issued EUA for the T-Detect COVID Test, a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2.
Read MoreFDA Authorizes First RASD for Performing Transvaginal Hysterectomy
FDA authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients.
Read MoreFDA Approves First Treatment for Molybdenum Cofactor Deficiency Type A
FDA approved Nulibry (fosdenopterin) for injection to reduce the risk of death due to Molybdenum Cofactor Deficiency Type A, a rare, genetic, metabolic disorder that typically presents in the first few days of life, causing intractable seizures, brain injury and death.
Read More